BioArctic Collaborates with BMS for its Pyroglutamate-Amyloid-Beta Antibody Programs
Shots:
- BioArctic & BMS have signed a global exclusive license agreement to develop PyroGlu-Aβ Ab programs, BAN1503 & BAN2803 (based on BioArctic’s BrainTransporter tech)
- BMS secures exclusive rights to develop & commercialize programs in exchange for $100M upfront, up to $1.25B development, regulatory & commercial milestones plus low double-digit tiered royalties, while BioArctic gets an co-commercialization option across the Nordic region
- The PyroGlu-Aβ antibody programs comprise of novel antibodies that target certain truncated, pyroglutamate modified form of amyloid-beta, the aggregates of which can cause cognitive & other symptoms in Alzheimer’s disease
Ref: PrNewsWire | Image: BMS & BioArctic
Related News:- BMS Reports the US FDA’s Approval of Opdivo Plus CT as a Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
